Results 11 to 20 of about 142 (121)

The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models

Journal of Fungi, 2021
Rezafungin is a novel echinocandin in Phase 3 development for prevention of invasive fungal disease caused by Candida spp., Aspergillus spp. and Pneumocystis jirovecii in blood and marrow transplantation patients.
Melanie T. Cushion, Alan Ashbaugh
doaj   +1 more source

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]

Drugs, 2021
The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and ...
Martin Hoenigl, Rosanne Sprute, Matthias Egger, Amir Arastehfar, Oliver A. Cornely, Robert Krause, Cornelia Lass-Flörl, Juergen Prattes, Andrej Spec, George R. Thompson, Nathan Wiederhold, Jeffrey D. Jenks   +11 more
openaire   +4 more sources

Promising antimycotics for the treatment of invasive infections [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj   +1 more source

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Clinical and Translational Science, 2022
Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of
Kenan Gu, Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang, Taylor Sandison, Shawn Flanagan   +6 more
doaj   +1 more source

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin [PDF]

Open Forum Infectious Diseases, 2021
Abstract Background Rezafungin (RZF) is a novel echinocandin antifungal being developed for treatment of candidemia and invasive candidiasis, and for prevention of invasive fungal diseases among immunosuppressed patients.
Huguet, Jade, Ong, Voon, Sandison, Taylor, Melara, Rebeca M, Marbury, Thomas C, Jandourek, Alena, Flanagan, Shawn   +6 more
openaire   +1 more source

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections

Antimicrobial Agents and Chemotherapy, 2021
Rezafungin is a novel antifungal agent of the echinocandin class with potent activity against species ofCandidaandAspergillus, including subsets of resistant strains, andPneumocystis jirovecii. The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the disposition of rezafungin in plasma following ...
Christopher M. Rubino, Shawn Flanagan
openaire   +2 more sources

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

Microorganisms, 2021
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates ...
Renátó Kovács, Zoltán Tóth, Jeffrey B. Locke, Lajos Forgács, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, László Majoros   +7 more
doaj   +1 more source

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Journal of Fungi, 2020
Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth, Lajos Forgács, Tamás Kardos, Renátó Kovács, Jeffrey B. Locke, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, Awid Adnan, László Majoros   +9 more
doaj   +1 more source

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program

Open Forum Infectious Diseases, 2023
Abstract Background Rezafungin (RZF) is a new echinocandin (ECH) approved by the US FDA to treat candidemia and invasive candidiasis (IC). Fluconazole (FLC) resistance (R) is a raising concern to treat IC, and ECHs are often used as first-line therapy.
Carvalhaes, Cecilia G, Rhomberg, Paul, Klauer, Abby, Castanheira, Mariana   +3 more
openaire   +1 more source

Echinocandins – structure, mechanism of action and use in antifungal therapy

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well.
Mateusz Szymański, Sandra Chmielewska, Urszula Czyżewska, Marta Malinowska, Adam Tylicki   +4 more
doaj   +1 more source